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C3d receptor (CR2) was first described as a receptor for C3d, distinct from
the C3b receptor (CRI), expressed by B lymphocytes (1, 2), and identified as a
glycoprotein of 140,000 Mr with an mAb anti-B2 (3). This same molecule serves
as the receptor for Epstein-Barr virus (4). Involvement of CR2 in a pathway of
B-lymphocyte activation has been suggested from studies using anti-CR2 (5, 6)
and multivalent C3d (7).
CRI, C4-binding protein (C4-bp), and factor H are encoded by tightly linked
genes (8), and cDNA sequencing studies show (9-11) that each protein contains
consensus repeating homology units of ^-60 amino acids. Moreover, they have
certain similarities in their function: accelerating decay of the C3 convertases
and serving as cofactors of C3b inactivator (1). Thus, it has been proposed that
they are part of a gene family of C3- and C4-regulatory proteins.
Weis et al. (12) identified a partial cDNA clone for CR2 that crosshybridized
with CRI cDNA probe, and showed a strong homology in tryptic peptide
sequences of CR2 and CR1 . Based on these findings, they postulated CR2 being
a member of the gene-family, although no regulatory activity shared with other
members had yet been shown.
In this report, we will demonstrate that CR2 has functional activity, serving as
a cofactor of I for the cleavage of membrane-bound iC3b into C3dg and C3c,
and that it shares antigenicity with CRI .
Materials and Methods
BriefDefinitive Report
Antibodies. Hybridoma cell line HB-5 secreting IgG2a monoclonal anti-CR2 was
obtained from American Type Culture Collection, Rockville, MD. OKB7, a IgG2a
monoclonal anti-CR2 was purchased from Ortho Diagnostic Systems Inc. (Westwood,
MA). mAbs 57H and 44D were against human CRI . As controls, other mAbs were used:
TKI, a IgGlx monoclonal anti-C4-bp; and 103A, a IgG2aa monoclonal anti-human
monocyte .
Complement Components and Intermediate Cells. Sheep erythrocytes sensitized with
rabbit hemolysin (EA) were reacted with large excess of guinea pig C1 and oxidized
human C2 and 30 site-forming units (SFU) of human C4, and then with 1251-labeled C3 .
They were converted to EAC14oxy23bi by incubation with I (2 ag/ml) and H (6 ug/ml)
at 37°C for 1 h, and referred to as EA 1251-iC3b.
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Immunoelectroblotting Analysis.
￿
After SDS-PAGE, samples were electrically transferred
to Hydrophobic Durapore sheets (Millipore Limited Co., Tokyo, Japan). The sheets were
soaked in 1 :2 dilution of PBS with distilled water (0.5 X PBS) containing 5% BSA for 30
min at room temperature, and then they were incubated with first antibody in 1 % BSA
and 0.5 X PBS containing 1% goat serum for 1 h. After washing with 0.05% Tween 20
in 0 .5 X PBS, the sheets were treated with Vectastain ABC kit (Vector Laboratories, Inc.,
Burlingame, CA).
Raji Cell Culture and Preparation ofthe Cell Lysate.
￿
About 10'° Raji cells were washed
twice with PBS and solubilized in 1 liter of 10 mM Tris-HC1 buffer, pH 8.3, containing
0.55% NP-40, 5 mM (p-Amidinophenyl) methanesulfonyl fluoride hydrochloride (p-
APMSF), 20 kg/ml soybean trypsin inhibitor, 100 rug/ml leupeptin, 0.1 Pg/ml pepstatin,
and 50 U/ml Trasilol with continuous stirring for 2 h in an ice bath. Nuclei and other
insoluble material were removed by centrifugation.
Purification of CR2.
￿
The detail of the first chromatography on DEAE-Toyopearl
(Toyosoda Co.) is described in the legend of Fig. 1 . CR2 pool was dialyzed and subjected
to the second ion exchange chromatography on SP-Toyopearl 6505 (1 .5 X 15 cm)
preequilibrated with 10 mM phosphate buffer, pH 6.2, containing 10 mM NaCl, 0.1 % 3-
[(3-cholamidopropyl)dimethylammoniol-l-propanesulfonate (Chaps) and inhibitors, 10
ug/ml leupeptin, 0.1 ug/ml pepstatin, and 5 mM p-APMSF. CR2 was eluted with salt
gradient at an NaCl concentration between 0.2 and 0.3 M. For further purification, a
CR2-enriched pool was applied to sequential columns of Sepharose-mouse IgG and
Sepharose-HB-5 at 6 ml/h at 4°C. The Sepharose-HB-5 column was washed successively
with 30 ml of 150 mM NaCl/20 mM Tris-HCl, pH 8.3, containing 0.1 % Chaps and the
inhibitors, with 30 ml of 150 mM NaCl/50 mM acetate, pH 4.5, containing the same
detergent and inhibitors, and finally with 30 ml of the same Tris buffer used in the first
wash. CR2 was eluted with 3M potassium thiocyanate containing 0.1% Chaps and the
inhibitors, followed by dialysis with PBS containing 0.1 % Chaps and then it was concen-
trated to 0.5 ml by centrifugation at 100,000 g for 2 h. Protein concentration of the final
CR2 preparation was determined by the method of Lowry using BSA as a standard.
Results
CR2 was purified from NP-40 lysate of Raji cells. Fig. 1a shows the elution
profile from DEAE-Toyopearl 6505. Degradation products of CR2 with various
sizes (120, 100, 17, 14, and 11 X 10s) were observed. After the second ion
exchange chromatography on SP-Toyopearl 6505, pooled fractions were com-
pletely free of degraded CR2 fragments. Since a small amount of CRI was
detected in the Raji cell lysate by immunoelectroblotting, the CR2 preparation
was treated with 100 ul of Sepharose-anti-CRI (57H + 44D) for 4 h at 4°C.
Finally, 120 1Ag of CR2 was obtained, and it was shown as a single Coomassie
blue-stained band on SDS-PAGE (Fig. 1 b).
Purified,CR2 was examined for its cofactor activity in the I-mediated cleavage
of membrane-bound iC3b. EA125I-iC3b were incubated with purified CR2,
washed, and then incubated with I. Substantial amounts of C3 radioactivity
(7.7%) were released upon incubation with buffer, I alone, or CR2 alone. 13.9%
of the radioactivity were released from the cells treated with CR2 plus 1, and
17.0% from cells treated with CRI plus I. The structural analysis on SDS-PAGE
indicatedthat iC3b, 75-kD chainand65-kD chain, was released fromthe controls.
An additional band of 31 kD was observed in the supernatants from cells
incubated with CR2 plus I or CR1 plus I under reducing conditions. And an
additional band of 140 kD was observed under nonreducing conditions, indicat-
ing that C3c was released. As already described, the 40 kD peptide was poorly
labeled (13). The release of C3c was inhibited when CR2 was pretreated with1426
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FIGURE 1.
￿
Purification ofCR2. 1 liter ofthe lysate was applied to aDEAE-Toyopearl column
(1.5 x 15 cm) preequilibrated with 10 mM Tris-HCI buffer, pH 8.3, containing 10 mM NaCl
and 0.5% NP-40 . The column was washed with Tris-HCl buffer containing 10 mM NaCl,
0.1% Chaps, 10 fag/ml leupeptin, 0.1 lug/ml pepstatin, and 5mM p-APMSF and was eluted
with a linear salt gradient at a flow rate of 3 ml/min . 10-ml fractions were collected and
assayed for CR2 by immmunoelectroblotting . The inset (a) shows the results of the assay,
indicating intact CR2 and degraded molecules were detected with HB-5 . (a) Fractions 34-43
were pooled. (b) 1 .2 Ag of purified CR2 was run on a 5-15% SDS-PAGE gradient gel under
reducing conditions and stained with Coomassie blue .
OKB7 anti-CR2, whereas no inhibition was observed with 103A control IgG2a
mAb. However, when CR2 was preincubated with 57H anti-CR1, partial inhi-
bition of C3c release was noticed (Fig. 2) . These results raised two possibilities :
(a) that CR2 crossreacted with 57H anti-CR1 and (b) that a small amount ofCR1
was present in theCR2 preparation . Toexclude the latter possibility, the amount
of possibly contaminating CR 1 in the CR2 preparation was measured by semi-
quantitative immunoelectroblotting where serially diluted CR1 and CR2 were
tested . The 140 kD band was the only band detected in the CR2 preparation
with 57H, even when 1 .2 jug of CR2 was loaded ; in this assay 0.6 ng of CR1
could be detected . To further confirm that CR2 but not CR1 did serve as a
cofactor o£ I, we tested whether CR2 could also act on membrane-bound C3b as
a cofactor of I . Three times more CR2 was necessary to achieve the similar
extent of C3c release from C3b (data not shown) . On the contrary, CRI was
more effective in serving as a cofactor of I for cleaving C3b than iC3b, as
previously reported (13) .
Next we examined the possibility that CR2 shares the antigenicity with CR 1
by immunoelectroblotting . 57H is an mAbagainst CR 1 that recognizes an epitopeMITOMO ET AL .
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FIGURE 2.
￿
SDS-PAGE analysis ofthe cleavage prod-
ucts released from EA125I-iC3b . CR2 (200 ng), CR1
(2.5 ng), or buffer were incubated with either antibody
(400 ng), OKB7, 57H, or 103A at 37°C for 30 min
before addition toEA 125I-iC3b (4 X 106 cells) in a total
volume of 80 ul . Aftera 30-min incubation with CR2,
CRI, or buffer, cells were washed twice and resus-
pended in 80 kl of the buffer, andthen 20 kl ofI (200
ng) or buffer were added . Aftera 30-min incubation
at 37°C, cells were centrifuged and the supernatants
were analyzed by SDS-PAGE 10% gel under reducing
conditions followed by radioautography. Isotonic ve-
ronal-buffered saline containing 2.5% dextrose, 0.15
mM CaCl2 , I MM MgC1 2 , supplemented with 0.1
mg/ml BSA was used in the assay.
FIGURE 3 .
￿
Crossreactivity of 57H anti-CRI with
CR2. Purified CRI and CR2 were run on 6.5%
SDS-PAGE and analyzed by immunoblotting as
follows : (1) CR2 (3 ng) detected with HB-5 ; (2)
CR1 (10 ng) detected with 57H; (3) CR2 (60 ng)
detected with 57H; (4) CRI (10 ng) detected with
TK1; (5) CR2 (60 ng) detected with TK1.
at or in the close proximity of the ligand binding site of the receptor. When a
fairly large amount (60 ng) of CR2 was used, it reacted with 57H but not with a
control mAb TK1 anti-C4bp (Fig. 3) . Crossreactivity of OKB7 with CRI,
however, was not detected .
Discussion
We investigated the functional and antigenic properties ofCR2 in its purified
form . No functional activity ofCR2 in regulation ofcomplement cascade has yet
been shown . IfCR2 has any regulatory function on C3, it can be expected to act1428
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on membrane-bound iC3b. This assumption was made because ofthe following
reasons. iC3b is recognized by CR2 as a better ligand than Cab with far higher
avidity (14), and moreover, the ligands of complement receptors are well recog-
nized when they are in clusters on immune complex or membrane. CR2 indeed
exhibited a cofactor activity of I in cleaving bound iC3b into C3dg and C3c. A
previous study by Weis et al. (15) showed that CR2 lacked functional activities;
it failed to accelerate the decay of C3 convertases and to serve as a cofactor of I
in cleaving fluid phase C3b. Therefore, this function, serving as a cofactor for
cleavage of bound iC3b by I, may be the only regulatory function of CR2 on
complement cascade. It could be argued, however, that a small amount of
contaminating CR1 in the CR2 preparation was responsible for the cofactor
activity. Several lines ofevidence excluded this possibility. First, the contaminat-
ing CR1 was estimated as <0.05% by a semiquantitative immunoelectroblotting.
Second, the cofactor activity of CR1 was completely inhibited when CR1 was
preincubated with 57H anti-CR1, while only partial inhibition by 57H was
observed for the cleavage with CR2 plus I (Fig. 2). Third, CR2 was more
effective on EAiC3b than on EAC3b, contrary to the effect of CR1. Thus it is
clear that CR2 is responsible for the cofactor activity.
Another important finding is that CR2 crossreacted with 57H monoclonal
anti-CR1 (Fig. 3). The crossreaction was indicated also in the functional assay
where 57H inhibited the CR2 plus I-mediated C3c release (Fig. 2). These results
suggest that CR2 and CR1 have similar structures in the site that is involved in
the regulatory function.
Taken together, our findings that CR2 has regulatory function on iC3b and
thatCR2 crossreacts with anti-CR1 implythat CR2 and CR1 may beevolutionally
related. The physiological role of the cofactor function of CR2 has to be
determined by further study since the activity was very weak, ^"120-400 times
less effective than CR1 on a weight basis. However, these observations will
provide further evidence to place CR2 as a new member of the gene family of
C3- and C4-regulatory proteins.
Summary
This is the first report demonstrating that Cad receptor (CR2) has functional
activity in regulating complement cascade. Purified CR2 was examined for its
cofactor activity in factor I-mediated cleavage of membrane-bound iC3b. CR2
plus C3b inactivator (I) released C3c from EA'25I-iC3b, and the release was
inhibited when CR2 was preincubated with OKB7 monoclonal anti-CR2 . Fur-
thermore, immunoelectroblotting analysis showed crossreactivity of CR2 with
57H anti-CR1 . These results indicate that CR2 has functional and antigenic
similarity to CR1, thus providing a supporting evidence for placement of CR2
as a member of the recently defined gene family of C3- and C4-regulatory
proteins composed of CR1, C4-binding protein, and factor H.
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